Antigens, CD20
Showing 1 - 25 of >10,000
Large B-cell Lymphoma Trial in Philadelphia (mosunetuzumab, glofitamab, obinutuzumab)
Recruiting
- Large B-cell Lymphoma
- mosunetuzumab
- +2 more
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Jul 21, 2022
CD20-positive Non-Hodgkin Lymphoma Trial in China (EX103 injection)
Recruiting
- CD20-positive Non-Hodgkin Lymphoma
- EX103 injection
-
Zhengzhou, Henan, China
- +3 more
Aug 28, 2023
Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute
Not yet recruiting
- Chronic Lymphocytic Leukemia
- +2 more
- Anti-CD19 and anti-CD20 bicistronic CAR T- cells
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Apr 10, 2023
Lymphoma Trial in Houston (PCV20)
Not yet recruiting
- Lymphoma
- PCV20
-
Houston, TexasM D Anderson Cancer Center
Sep 20, 2023
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia
Recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +5 more
- CAR-20/19-T cells (1 x 10^5 CAR-20/19-T cells/kg)
- +4 more
-
Milwaukee, WisconsinMedical College of Wisconsin
Sep 22, 2022
HBV Reactivation in Anti CD20 Treatment
Active, not recruiting
- Hepatitis B
-
Afula, Tsafon, IsraelHaEmek Medical Center
Mar 14, 2023
Relapsing Multiple Sclerosis Trial in Fort Collins, Farmington (Ublituximab)
Recruiting
- Relapsing Multiple Sclerosis
- Ublituximab
-
Fort Collins, Colorado
- +1 more
May 26, 2023
Nephrotic Syndrome Trial in Genova (Rituximab Biosimilar ABP 798, Daratumumab)
Not yet recruiting
- Nephrotic Syndrome
- Rituximab Biosimilar ABP 798
- Daratumumab
-
Genova, ItalyIRCCS G. Gaslini
Jan 19, 2023
B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL Trial in Louisville (Cyclophosphamide, Fludarabine, ACE1831)
Recruiting
- B-cell Lymphoma
- +5 more
- Cyclophosphamide
- +3 more
-
Louisville, KentuckyNorton Cancer Institute
Jan 24, 2023
Follicular Lymphoma, Mantle Cell Lymphoma Trial in Rouen (Determination of COVID-19 vacciantion efficacy)
Completed
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Determination of COVID-19 vacciantion efficacy
-
Rouen, FranceCentre Henri Becquerel
Dec 22, 2022
CD20-positive B-cell Non-Hodgkin's Lymphoma Trial in Beijing (IMM0306)
Recruiting
- CD20-positive B-cell Non-Hodgkin's Lymphoma
-
Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Apr 6, 2023
CD20-positive Non-Hodgkin Lymphoma Trial in Seoul (Rituximab + MG4101)
Terminated
- CD20-positive Non-Hodgkin Lymphoma
- Rituximab + MG4101
-
Seoul, Korea, Republic ofSeoul National University Hospital
Oct 24, 2022
Primary Membranous Nephropathy Trial in Beijing (B007)
Not yet recruiting
- Primary Membranous Nephropathy
-
Beijing, ChinaPeking university first hospital
Dec 20, 2022
Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial
Recruiting
- Recurrent Acute Lymphoblastic Leukemia
- +15 more
- Anti-CD19/CD20/CD22 CAR T-Cells
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 4, 2022
Systemic Lupus Erythematosus, Pulmonary Arterial Hypertension Trial in Beijing (Rituximab)
Not yet recruiting
- Systemic Lupus Erythematosus
- Pulmonary Arterial Hypertension
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Apr 13, 2023
Lymphoma, B-Cell Trial in Langfang (CD19 and CD22 targeted CAR-T cells)
Not yet recruiting
- Lymphoma, B-Cell
- CD19 and CD22 targeted CAR-T cells
-
Langfang, Hebei, ChinaHebei Yanda Ludaopei Hospital
Dec 6, 2022
COVID-19 Infection in Patients Receiving Anti-CD20 Therapy
Active, not recruiting
- COVID-19
- +3 more
- Convalescent Plasma
-
Rochester, MinnesotaMayo Clinic
Jul 15, 2022
Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Chronic Lymphocytic Leukemia Trial in Milwaukee (CAR-20/19-T cells (1.0 x10^5
Completed
- Lymphoma, Non-Hodgkin
- +3 more
- CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)
- +3 more
-
Milwaukee, WisconsinFroedtert Hospital & Medical College of Wisconsin
Jun 26, 2022
Resolved Hepatitis B, CD20 Positive B-cell Lymphoma Trial (Entecavir)
Not yet recruiting
- Resolved Hepatitis B
- CD20 Positive B-cell Lymphoma
- (no location specified)
Jul 10, 2022
B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in China (Orelabrutinib, Recombinant humanized mAb MIL62 injection)
Active, not recruiting
- B-cell Lymphoma Recurrent
- B-cell Lymphoma Refractory
- Orelabrutinib
- Recombinant humanized monoclonal antibody MIL62 injection
-
Bengbu, Anhui, China
- +9 more
Nov 11, 2022
Leukemia, Stem Cell Transplantation Trial in Munich (FBTA05)
Withdrawn
- Leukemia
- Stem Cell Transplantation
-
Munich, Bavaria, Germany3. Medizinische Klinik, Klinikum rechts der Isar der TU München
Dec 5, 2022
Lymphoma, Follicular, Lymphoma, Mantle-Cell, Marginal Zone Lymphoma Trial in United States (ADI-001, Fludarabine,
Recruiting
- Lymphoma, Follicular
- +5 more
- ADI-001
- +2 more
-
Stanford, California
- +6 more
Oct 19, 2022
Aplastic Anemia Trial in Suzhou (CD20 mAb, ATG)
Recruiting
- Aplastic Anemia
- CD20 monoclonal antibody
- ATG
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Aug 21, 2022
Lymphoma, B-Cell, Lymphoma, Non-hodgkins, Chronic Lymphocytic Leukemia Trial run by the NCI (Anti-cluster of differentiation 19
Terminated
- Lymphoma, B-Cell
- +3 more
- Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptors (CAR) and Anti-cluster of differentiation 20 (CD20)-CAR T cells
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 26, 2022